McKesson price target raised to $201 from $182 at FBR Capital FBR Capital raised its price target for McKesson shares to $201 citing the company's strong Q3 results and keeps an Outperform rating on the stock. FBR says McKesson remains a top pick.
News For MCK From The Last 14 Days
Check below for free stories on MCK the last two weeks.
McKesson extends pharmaceutical distribution agreement with CVS Caremark McKesson Corporation (MCK) announced a three-year extension of its existing distribution agreement with CVS Caremark (CVS) through June, 2019. “We have a long track record of delivering comprehensive supply chain solutions to CVS Caremark which in turn allows CVS Caremark to ensure the highest level of pharmaceutical care to its customers,” said Paul Julian, executive vice president, group president, McKesson Corporation. “We are pleased to have extended our agreement with CVS Caremark and continue our long standing partnership.”